SK-Hep-1

sk-hep1 /sk-hep1 细胞系/sk-hep1 细胞株/sk-hep1 人肝癌细胞

Cell line name SK-HEP-1

Synonyms SK-Hep-1; SK HEP-1; SK HEP 01; SK-Hep1; Sk-Hep1; SK Hep1; SKHEP-1; SKHEP1; SKHep1; SK_HEP1

Accession CVCL_0525

Resource Identification Initiative To cite this cell line use: SK-HEP-1 (RRID:CVCL_0525)

Comments Problematic cell line: Misclassified. Originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells (PubMed=1371504; PubMed=31938418).

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-535.

Population: Caucasian.

Doubling time: 46.7 +- 10.3 hours, 94.2 hours (Note=In CDM4-CHO medium), 289.8 hours (Note=In 293 SFM II medium) (PubMed=25822314); ~30 hours (DSMZ=ACC-141).

Karyotypic information: Has lost chromosome Y.

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Secretome proteome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.

Cell type: Endothelial cell; CL=CL_0000115.

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

 

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x

Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.-J., Revillard J.-P.

Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.

Eur. J. Biochem. 165:699-704(1987)

 

PubMed=1371504; DOI=10.1007/BF02631017

Heffelfinger S.C., Hawkins H.H., Barrish J., Taylor L., Darlington G.J.

SK HEP-1: a human cell line of endothelial origin.

In Vitro Cell. Dev. Biol. Anim. 28:136-142(1992)

 

PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613

Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.

Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.

FASEB J. 7:1407-1413(1993)

 

PubMed=8389256; DOI=10.1093/carcin/14.5.987

Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.

p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.

Carcinogenesis 14:987-992(1993)

 

PubMed=9023415; DOI=10.1006/cimm.1996.1062

Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.

Cell. Immunol. 175:101-110(1997)

 

PubMed=9178645; DOI=10.1006/cimm.1997.1108

Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.

CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.

Cell. Immunol. 177:176-181(1997)

 

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

 

PubMed=12029633; DOI=10.1053/jhep.2002.33683

Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.

TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.

Hepatology 35:1476-1484(2002)